Palatin Technologies, Inc.

Cranbury, NJ 08512

SBIR Award Summary

Total Number of Awards 26
Total Value of Awards $1.21MM
First Award Date 09/30/86
Most Recent Award Date 03/01/02

Key Personnel

Last Name Name Awards Contact
Rhodes Buck A Rhodes 7
Coons Teresa Coons 2
Zamora Paul O Zamora 3
Ma'Ayan Ari Ma'Ayan 1
Sharma Shubh D Sharma 7
Thakur Mathew L Thakur 4
Smith Terry D Smith 1
Blood Christine H Blood 1

26 Awards Won

Phase 2 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 03/01/02 - 02/29/04

DESCRIPTION (Applicant's abstract verbatim): Each year in the USA, more than 500,000 patients are hospitalized with venous thrombosis (VT) and pulmonary embolism (PE). Of these patients, nearly 200,000 die. Despite the magnificent advances in imaging techniques, diagnosis of VT and PE continues to be challen...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 03/01/01 - 02/28/02

DESCRIPTION (Applicant's abstract verbatim): Each year in the USA, more than 500,000 patients are hospitalized with venous thrombosis (VT) and pulmonary embolism (PE). Of these patients, nearly 200,000 die. Despite the magnificent advances in imaging techniques, diagnosis of VT and PE continues to be challen...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/17/00 - 10/16/00

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/00 - 09/30/01

The objective is development of a rationally designed 99mTc-peptide radio- pharmaceutical for scintigraphic detection and localization of infection/ inflammation foci. The designed peptide is based on natural tetrapeptide tuftsin, a component of immune response network. Binding of tuftsin to its candidate as an in vivo inflammation imaging agent...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/99 - 03/31/00

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/15/99 - 03/14/00

DESCRIPTION (Adapted from the application): Low molecular peptides are ligands for a number of types of receptors. Delivery of peptides by an intranasal route would circumvent the problems of administering them by injection. This application is designed to 1) develop an intranasal formulation of Melanotan-II (MT-II),...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/99 - 10/31/00

DESCRIPTION: The investigators propose to test the feasibility of developing a radiopharmaceutical based on Tc-99m-labeled vasoactive intestinal peptide for receptor-specific uptake on tumors with over-expression, as further described by their abstract: ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/99 - 03/31/00

The objective is development of a rationally designed 99mTc-peptide radio- pharmaceutical for scintigraphic detection and localization of infection/ inflammation foci. The designed peptide is based on natural tetrapeptide tuftsin, a component of immune response network. Binding of tuftsin to its candidate as an in vivo inflammation imaging agent...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/99 - 09/30/99

An MC-4 receptor (melanocortin-4 receptor-specific) agonist metallopeptide will be developed for investigation as a therapeutic agent to modify energy metabolism and feeding behavior, including treatment of pathologic obesity and related conditions. In Phase I, a directed combinatorial library of metallopeptides will be screened against the MC-...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/98 - 09/29/99

DESCRIPTION: The investigators propose to test the feasibility of developing a method for nuclear medical imaging of thromboembolism with a technetium-99m-labeled CSVTCG peptide fragment of thrombospondin protein, both of which bind to the major platelet glycoprotein, CD36, as further described by their abst...

Load More